Literature DB >> 11156553

Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity.

M J Field1, R J Oles, L Singh.   

Abstract

The present study examines the effect of pregabalin (previously S-Isobutylgaba and CI-1008) in two distinct rat models of anxiety. Pregabalin binds with high affinity and selectivity to the alpha(2)delta subunit of voltage dependent calcium channels (VDCC). Its corresponding R-enantiomer (R-isobutylgaba) is approximately 10 fold weaker. Pregabalin dose-dependently induced anxiolytic-like effects in both the rat conflict test and elevated X-maze with respective minimum effective doses (MED) of 3 and 10 mg kg(-1). In contrast, R-isobutylgaba only showed activity at the highest dose of 100 mg kg(-1) in the conflict test. These data indicate that pregabalin may possess clinical utility as a novel anxiolytic agent and demonstrates the importance of the alpha(2)delta subunit of VDCC in the mediation of anxiety related behaviours.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11156553      PMCID: PMC1572552          DOI: 10.1038/sj.bjp.0703794

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

Review 1.  Benzodiazepines: use, abuse, and consequences.

Authors:  J H Woods; J L Katz; G Winger
Journal:  Pharmacol Rev       Date:  1992-06       Impact factor: 25.468

Review 2.  Auxiliary subunits of voltage-gated ion channels.

Authors:  L L Isom; K S De Jongh; W A Catterall
Journal:  Neuron       Date:  1994-06       Impact factor: 17.173

Review 3.  Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?

Authors:  M H Lader
Journal:  Eur Neuropsychopharmacol       Date:  1999-12       Impact factor: 4.600

4.  The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist.

Authors:  L Singh; M J Field; J Hughes; R Menzies; R J Oles; C A Vass; G N Woodruff
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

5.  The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine.

Authors:  L Singh; M J Field; P Ferris; J C Hunter; R J Oles; R G Williams; G N Woodruff
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

Review 6.  Molecular basis for Ca2+ channel diversity.

Authors:  F Hofmann; M Biel; V Flockerzi
Journal:  Annu Rev Neurosci       Date:  1994       Impact factor: 12.449

Review 7.  Cholecystokinin and anxiety: promises and pitfalls.

Authors:  R J Rodgers; N J Johnson
Journal:  Crit Rev Neurobiol       Date:  1995

8.  The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel.

Authors:  N S Gee; J P Brown; V U Dissanayake; J Offord; R Thurlow; G N Woodruff
Journal:  J Biol Chem       Date:  1996-03-08       Impact factor: 5.157

9.  Localization of [3H]gabapentin to a novel site in rat brain: autoradiographic studies.

Authors:  D R Hill; N Suman-Chauhan; G N Woodruff
Journal:  Eur J Pharmacol       Date:  1993-02-15       Impact factor: 4.432

10.  Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin.

Authors:  C P Taylor; M G Vartanian; P W Yuen; C Bigge; N Suman-Chauhan; D R Hill
Journal:  Epilepsy Res       Date:  1993-01       Impact factor: 3.045

View more
  16 in total

Review 1.  Pregabalin: a review of its use in fibromyalgia.

Authors:  Katherine A Lyseng-Williamson; M Asif A Siddiqui
Journal:  Drugs       Date:  2008       Impact factor: 9.546

2.  Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat.

Authors:  Serena Stopponi; Lorenzo Somaini; Andrea Cippitelli; Giordano de Guglielmo; Marsida Kallupi; Nazzareno Cannella; Gilberto Gerra; Maurizio Massi; Roberto Ciccocioppo
Journal:  Psychopharmacology (Berl)       Date:  2011-09-02       Impact factor: 4.530

3.  Anxiolytic effects of the novel α2δ ligand mirogabalin in a rat model of chronic constriction injury, an experimental model of neuropathic pain.

Authors:  Hiroyasu Murasawa; Hiroyuki Kobayashi; Kensuke Saeki; Yutaka Kitano
Journal:  Psychopharmacology (Berl)       Date:  2019-09-12       Impact factor: 4.530

4.  Pregabalin: in the treatment of generalised anxiety disorder.

Authors:  James E Frampton; Rachel H Foster
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  A single injection of pregabalin induces short- and long-term beneficial effects on fear memory and anxiety-like behavior in rats with experimental type-1 diabetes mellitus.

Authors:  Alvaro Henrique Bernardo de Lima Silva; Debora Rasec Radulski; Gabriela Saidel Pereira; Alexandra Acco; Janaina Menezes Zanoveli
Journal:  Metab Brain Dis       Date:  2022-03-03       Impact factor: 3.584

Review 6.  Generalised anxiety disorder: treatment options.

Authors:  John J Sramek; Victoria Zarotsky; Neal R Cutler
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  Antiepileptic drugs in the treatment of anxiety disorders: role in therapy.

Authors:  Michael Van Ameringen; Catherine Mancini; Beth Pipe; Mark Bennett
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Cancer pain and anxiety.

Authors:  Paul D Thielking
Journal:  Curr Pain Headache Rep       Date:  2003-08

9.  The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic.

Authors:  Jeffrey R Strawn; Thomas D Geracioti
Journal:  Neuropsychiatr Dis Treat       Date:  2007-04       Impact factor: 2.570

10.  New treatment options in the management of fibromyalgia: role of pregabalin.

Authors:  Grazyna Zareba
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.